REGENXBIO Inc. (RGNX), a clinical-stage biotechnology company focused on gene therapy, announced late Wednesday that it has priced an underwritten upsized public offering of around 4.57 million shares of its common stock at the price of $23.00 per share. The company has also priced around 1.52 million pre-funded warrants at a price of $22.9999 per warrant.
In each case, the pricing was before underwriting discounts and commissions.
REGENXBIO expects the gross proceeds from the offering to be around $140.0 million. The offering is expected to close on March 11, subject to customary closing conditions.
In addition, the company has has granted the underwriters a 30-day option to purchase an additional 913,050 shares of common stock at the public offering price.
In the offering, Morgan Stanley, Goldman Sachs & Co. LLC, Barclays and Stifel are acting as joint book-running managers.
For comments and feedback contact: editorial@rttnews.com
Business News
May 01, 2026 15:54 ET Central banks dominated the economics news flow this week with almost all major ones announcing their latest policy decisions and many boosted expectations for a rate hike in June. In other news, several countries released the preliminary data for first quarter economic growth. In the U.S., comments by Fed Chair Jerome Powell were also in focus as his term ends this month.